- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06956131
Alterações de metabólitos após o consumo de diferentes bebidas proteicas em idosos de Cingapura
The study aims to investigate the acute effects of different protein sources (i.e., casein, whey, soy) on metabolomic profiles (e.g., amino acids in the blood), along with other outcomes such as cognitive function, mood, and appetite. While the study does not directly aim to prevent, prognosticate, diagnose, or alleviate any disease, it may provide insights that could inform dietary recommendations and support disease prevention efforts in older adults.
Visão geral do estudo
Status
Condições
Descrição detalhada
This study will be a double-blind, randomised, placebo-controlled trial using a crossover study design. 25 older adults (aged 60 to 80) will be recruited and assigned to consume 4 different test drinks in a random order on 4 different visits. This study aims to investigate whether higher protein consumption of different sources will influence postprandial plasma and urinary metabolomic profiles, cognition, mood and appetite. The study will comprise 1 screening visit and 4 test visits separated separated by a minimum washout period of >7 days
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Singapore, Cingapura, 117550
- NUS, Department of Food Science and Technology, 1 Science Drive 3, Block S13, #03-07
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- English-literate and able to give informed consent
- Adults 60 to 80 years old (inclusive)
- (If applicable) Postmenopausal
- BMI of 18·5 to 30 kg/m2 (inclusive)
Exclusion Criteria:
-
Currently participating in another clinical study that involves altering the regular diet and/or involves consuming a dietary supplement or investigated food product as an intervention
-
Weight change >3 kg in the past 3 months
-
Exercising vigorously over the past 3 months (i.e., engaging in high-intensity exercises for more than 3 hours a week, where high-intensity exercises leave one out of breath and unable to talk or sing during the workout)
-
Current smokers or have quit smoking for less than 5 years
-
Drinking >2 alcoholic drinks per day (i.e., one drink is defined as either 150 ml of wine, 340 ml of beer/cider or 45 ml of distilled spirit)
-
If drinking ≤2 alcoholic drinks per day, not willing to stop consumption of alcoholic beverages two days before and on the day of the test visits (total 12 days)
-
Not willing to stop consumption of caffeinated beverages 10 to 12 hours before and on the day of the test visits (total 4 days)
-
Taking supplements containing omega-3, magnesium, gamma-aminobutyric acid (GABA), L-theanine, melatonin and/or 5-hydroxytryptophan for the past 3 months, and not willing to discontinue usage 3 months before and during the study duration
-
Currently on a specialised diet (e.g., vegetarian, vegan, weight loss diet)
- Had serious food allergies in the past, or having intolerance, sensitivities or allergies to any of the following: milk/dairy products (e.g., casein, whey), starch/starch-derived products (e.g., rice, corn, wheat, potato), soy/soy-derived products, gluten, eggs, nuts, peanuts, fish and crustaceans.
-
Disease or impairment of the kidney and/or liver
-
Currently diagnosed with diabetes, sleep disorders, gastrointestinal issues (e.g., lactose intolerance, irritable bowel syndrome), gout and/or G6PD deficiency
-
History of diseases known to affect the central nervous system (e.g., heart disease, stroke, migraine headaches, multiple sclerosis, Parkinson's disease, mental illnesses)
-
Taking antibiotics 2 weeks prior to study participation
-
Taking medication known to interfere with cognitive function and mental wellbeing (e.g., benzodiazepines, antidepressants, other central nervous agents)
-
Taking anti-hypertensive or cholesterol-lowering drugs for less than 3 years unless medically declared by an official doctor to be in stable condition
-
Poor peripheral venous access based on past experiences with blood drawing
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Casein Protein Drink
30 g protein equivalent of casein protein isolate dissolved in ~250 mL of water |
30 g protein equivalent of casein protein isolate dissolved in ~250 mL of water |
|
Experimental: Whey Protein Drink
30 g protein equivalent of whey protein isolate dissolved in ~250 mL of water |
30 g protein equivalent of whey protein isolate dissolved in ~250 mL of water |
|
Experimental: Soy Protein Drink
30 g protein equivalent of soy protein isolate dissolved in ~250 mL of water |
30 g protein equivalent of soy protein isolate dissolved in ~250 mL of water |
|
Comparador de Placebo: Maltodextrin Drink
30 g carbohydrate equivalent of maltodextrin powder dissolved in ~250 mL of water |
30 g carbohydrate equivalent of maltodextrin powder dissolved in ~250 mL of water |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Changes in metabolites found in plasma (plasma metabolomics)
Prazo: Baseline, 15, 30, 60, 90, 120, 180, 240, 300 minutes
|
Untargeted metabolomics profiling of plasma will be conducted using ultra performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-QTOF-MS) |
Baseline, 15, 30, 60, 90, 120, 180, 240, 300 minutes
|
|
Changes in metabolites found in urine (urinary metabolomics)
Prazo: Baseline, 60, 120, 180, 240, 300 minutes
|
Untargeted metabolomics profiling of urine will be conducted using ultra performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-QTOF-MS) |
Baseline, 60, 120, 180, 240, 300 minutes
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cognitive Function
Prazo: Baseline, 15, 60, 120, 180, 240, 300 minutes
|
The Computerised Mental Performance Assessment System (COMPASS) will be administered via a laptop. The COMPASS tests consist of 5 consecutive tests, including Digit Vigilance, Stroop, Rapid Visual Information Processing, Computerised Corsi Blocks Lite, Alphabetic Working Memory and Serial Subtraction, where the correctness and reaction time will be recorded. The test is expected to take around 15 minutes. |
Baseline, 15, 60, 120, 180, 240, 300 minutes
|
|
Mood
Prazo: Baseline, 15, 60, 120, 180, 240, 300 minutes
|
The Profile of Mood States (POMS) questionnaire will be administered, which contains various words that describe feelings. Participants will indicate, for each word, how they currently feel on scale of 0 (Not at all) to 4 (Extremely). |
Baseline, 15, 60, 120, 180, 240, 300 minutes
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jung Eun Kim, Ph.D., R.D., National University of Singapore, Department of Food Science and Technology
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- S31
- NUS-IRB-2025-19 (Outro identificador: National University of Singapore Institutional Review Board (NUS IRB))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Electronic copies of the data with identifiable participant information will be kept on NUS OneDrive with access limited only Dr Kim Jung Eun and her research staff. All data will be de-identified prior to statistical analyses.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .